Drug
Ensovibep
Ensovibep: highest development phase Phase 2/3, developed by Molecular Partners, Novartis. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Molecular Partners, Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| ensovibep NCT04828161 | Phase 2/3 | COVID-19 |
| ensovibep NCT04834856 | Phase 2 | Covid19 |
| Ensovibep NCT04870164 | Phase 1 | COVID-19 |
Latest
No recent events.
Follow Ensovibep on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.